

# Spinal Cord Injury - Pipeline Review, H1 2020

<https://marketpublishers.com/r/S41DE21577CEN.html>

Date: May 2020

Pages: 243

Price: US\$ 2,000.00 (Single User License)

ID: S41DE21577CEN

## Abstracts

Spinal Cord Injury - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury – Pipeline Review, H1 2020, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.

Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant

and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 7, 10, 3, 33 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 13 molecules, respectively.

Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## **SCOPE**

The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

## Contents

Introduction

Spinal Cord Injury - Overview

Spinal Cord Injury - Therapeutics Development

Spinal Cord Injury - Therapeutics Assessment

Spinal Cord Injury - Companies Involved in Therapeutics Development

Spinal Cord Injury - Drug Profiles

Spinal Cord Injury - Dormant Projects

Spinal Cord Injury - Discontinued Products

Spinal Cord Injury - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Spinal Cord Injury, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Spinal Cord Injury - Pipeline by 9 Meters Biopharma Inc, H1 2020

Spinal Cord Injury - Pipeline by AbbVie Inc, H1 2020

Spinal Cord Injury - Pipeline by Admirx Inc, H1 2020

Spinal Cord Injury - Pipeline by Algiax Pharmaceuticals GmbH, H1 2020

Spinal Cord Injury - Pipeline by Aposcience AG, H1 2020

Spinal Cord Injury - Pipeline by Athersys Inc, H1 2020

Spinal Cord Injury - Dormant Projects, H1 2020

Spinal Cord Injury - Dormant Projects, H1 2020 (Contd..1), H1 2020

Spinal Cord Injury - Dormant Projects, H1 2020 (Contd..2), H1 2020

Spinal Cord Injury - Dormant Projects, H1 2020 (Contd..3), H1 2020

Spinal Cord Injury - Dormant Projects, H1 2020 (Contd..4), H1 2020

Spinal Cord Injury - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Spinal Cord Injury, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

9 Meters Biopharma Inc  
AbbVie Inc  
Admirx Inc  
Algiax Pharmaceuticals GmbH  
Aposcience AG  
Athersys Inc  
Axoltis Pharma SAS  
BioAxone BioSciences Inc  
Cellatoz Therapeutics Inc  
CellCure  
CSL Ltd  
CSPC Pharmaceutical Group Ltd  
Daewoong Pharmaceutical Co Ltd  
DeckTherapeutics Inc  
EUSOL Biotech Co Ltd  
Fortuna Fix Inc  
GABA Therapeutics Inc  
Gene Techno Science Co Ltd  
GNT Pharma Co Ltd  
Helixmith Co Ltd  
Hemostemix Inc

Hibernaid Inc  
Histocell SL  
Hope Biosciences LLC  
K-Stemcell Co Ltd  
Karyopharm Therapeutics Inc  
Kringle Pharma Inc  
Lineage Cell Therapeutics Inc  
Locate Bio Ltd  
Mapreg SAS  
Mitsubishi Tanabe Pharma Corp  
NervGen Pharma Corp  
NeuExcell Therapeutics Inc  
Neuroplast BV  
New World Laboratories Inc  
Novago Therapeutics AG  
Novartis AG  
Novoron Bioscience Inc  
NuNerve Pty Ltd  
Pharmatrophix Inc  
Pharmazz Inc  
Pharmicell Co Ltd  
Q Therapeutics Inc  
Radikal Therapeutics Inc  
ReNetX Bio  
RespireRx Pharmaceuticals Inc  
SanBio Inc  
Seneca Biopharma Inc  
StemCyte Inc  
Stemmedica Cell Technologies Inc  
Sumitomo Dainippon Pharma Co Ltd  
TechnoPhage SA  
Truvitech LLC  
Tumorend LLC  
Xcelthera INC  
ZyVersa Therapeutics Inc



## I would like to order

Product name: Spinal Cord Injury - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/S41DE21577CEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S41DE21577CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970